Hadassah

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Monday, Aug 14 2017

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

CDI, often also called C. difficile, is caused by a bacterial toxin that inflames the colon. It is especially found in hospitals and long-term, in-patient care facilities. Approximately 500,000 people annually contract CDI in the U.S. alone and about 20 percent experience a recurrence.

The new product, called IMM-529, is a naturally produced biological antibody, intended to prevent and treat CDI, as well as stop recurrence. As a polyclonal antibody, it generates highly specific antibodies to fight the three main sources of CDI: Toxin B, the highly infectious spores, and the vegetative cells in the gut. In addition, IMM-529 has been shown to rebalance the diversity of bacteria in the gut, which is often disrupted by antibiotics.

This first-ever human study will assess whether IMM-529 is safe and well tolerated by the participants and will also evaluate the preliminary efficacy of IMM-529. Pre-clinical studies with mice at Monash University in Melbourne, Australia, revealed 80 percent efficacy in preventing and treating CDI and 77.8 percent success in preventing recurrence. The control group of mice, in contrast, which only received the standard-of-care antibiotic, vancomycin, experienced a mortality rate of 88.9 percent.

In this human trial, 60 patients who have been diagnosed with CDI and treated with standard-of-care antibiotics, will be enrolled within three weeks of their diagnosis. Some will be randomly selected to receive IMM-529 three times daily and the others will receive a placebo for 28 days.

Read more at: http://www.immuron.com/assets/Uploads/Red-Chip-C-Difficile-Analyst-Report-Jan-2016.pdf

Read about another IMMURON clinical trial at Hadassah http://www.hadassah.org/news-stories/fatty-liver-us-trials.html

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Monday, Dec 10 2018

A Nurses Council Celebration in Israel: The Milestone Mission

We were honored to meet so many dynamic Hadassah nurses, some longtime and some new members--all of us excited to be together to celebrate the 100th anniversaries of the Hadassah Medical Organization, the Henrietta Szold Hadasssah-Hebrew University Nursing School and HMO's Department of Ophthalmology. And Israel's 70th

READ MORE ›
alt_text

Wednesday, Dec 5 2018

Prof. Chowers’ Long and Meaningful Hadassah Connections

Sophie Szold, mother of Hadassah founder Henrietta, wept when she saw children with flies in their eyes on their maiden trip to pre-state Israel in 1909. Those children had trachoma, endemic in the Middle East in those days.

READ MORE ›
alt_text

Wednesday, Dec 5 2018

Ending the Violence Against Women: Hadassah Staff Joins Nationwide Protests

On December 4, employees from both Hadassah Hospital Ein Kerem and Hadassah Hospital Mount Scopus rallied to end violence against women. “Together we will banish the darkness and return the light to all women,” read banners held by the participants.

READ MORE ›
alt_text

Tuesday, Dec 4 2018

No Ovaries? Mystery Solved By Hadassah Endocrinologist

A few years ago, a mother brought her teenage daughter to see Prof. David Zangen, Director of Pediatric Endocrinology at the Hadassah Medical Organization.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More